

http://pubs.acs.org/journal/acsodf

Article

Scalable and clean synthetic methods

Green Protocol for the Novel Synthesis of Thiochromeno[4,3-b]pyridine and Chromeno[4,3-b]pyridine Derivatives Utilizing a High-Pressure System

Haider Behbehani,* Kamal M. Dawood, Fatemah A. Aryan, and Hamada Mohamed Ibrahim*



well as being scalable and having a high atom economy. The proposed mechanistic route includes two sequential dehydrative stages. In this investigation, X-ray crystallographic analysis was performed to authenticate the targeted products.

INTRODUCTION

Fusion of chromene with pyridine can form two interesting classes of tricyclic systems such as chromeno[2,3-b]pyridines and chromeno[4,3-b]pyridines. The chromeno[2,3-b]pyridines had a wide range of pharmacological potentialities and were found in two anti-inflammatory commercial drugs: amlexanox^{1,2} and pranoprofen (Figure 1).³ Chromeno[4,3-b]-pyridine derivatives are also an interesting class of three-

substrate scope, and simple work-up and purification processes, as



Figure 1. Some biologically active chromanone-containing compounds.

fused heterocycles with broad medicinal and biological importance.⁴ Some chromeno[4,3-*b*]pyridine derivatives were reported to have potential anticancer,^{5–9} anti-inflammatory,¹⁰ antimicrobial,^{11,12} and antifibrotic activities¹³ and estrogen receptor β -selective ligands¹⁴ as well as TNF- α inhibitors.¹⁵ Four naturally occurring chromeno[4,3-*b*]pyridine derivatives (**A**-**D**) were isolated from a fungus *Phomopsis sp.* and exhibited good antioxidant activity (Figure 1).¹⁶ Moreover, the thiochromeno-containing compounds demonstrated potent biological properties,¹⁷ for example, and, not for all, they can act as antibacterial,^{18–20} antioxidant,²⁰ antifungal,^{21,22} antiviral,²³ antitumor,²⁴ and anticancer agents.²⁵ Furthermore, some members exhibited herbicidal^{26,27} and insecticidal²⁸ activity.

Easy operation and purification

Broad substr

Due to their high biological activity, various synthetic approaches were examined by researchers for the preparation of the chromeno[4,3-b]pyridine skeletons. The reported synthetic routes included: (1) reaction of 3-arylidene-4-chromanone acyl pyridinium iodide salts,^{5,8,9} (2) intra-molecular heterocyclization of *O*-propargylated aromatic hydroxyaldehydes,²⁹ and (3) intramolecular Diels–Alder cycloadditions of *O*-propargylated azadienyl benzene³⁰ or 3-

Received: October 3, 2021 Accepted: November 17, 2021 Published: November 30, 2021





© 2021 The Authors. Published by American Chemical Society

Scheme 1. Reactions of Thiochroman-4-one 1a and Arylhydrazonal 2a



Table 1. Optimization of the Reaction between Thiochroman-4-one 1a and Arylhydrazonal 2a^a

$ \begin{array}{c} & & & & \\ & & & &$							
entry	solvent	additive	T (°C)	time	product (% yield) ^c		
1	1,4-dioxane	AcONH ₄	reflux	18 h			
2	DMF	AcONH ₄	reflux	18 h			
3	CH ₃ CN	AcONH ₄	reflux	18 h			
4	EtOH	AcONH ₄	reflux	18 h			
5	propanol	AcONH ₄	reflux	18 h			
6	AcOH	AcONH ₄	reflux	6 h	45 ^a		
7	AcOH	AcONH ₄	Q-tube (155 °C) ^b	45 min	82 ^{<i>a</i>}		
8	AcOH	AcONH ₄	Q-tube (160 °C)	45 min	86		
9	AcOH	AcONH ₄	Q-tube (165 °C)	45 min	91		
10	AcOH	AcONH ₄	Q-tube (170 °C)	45 min	93		

^aReaction conditions: thiochroman-4-one **1a** (5 mmol), arylhydrazonal **2a** (5 mmol), and ammonium acetate (10 mmol) in acetic acid (15 mL). ^bTemperature of the oil bath. ^cIsolated yield.

(O-propynyloxyphenyl)-triazine.³¹ A little attention has been paid toward the biologically active thiochromeno[2,3-b]pyridine derivatives^{32,33} where few synthetic routes for some examples of thiochromeno[2,3-b]pyridines were published.³⁴⁻³⁷ Apart from this, only one publication for the synthesis of the thiochromeno [4,3-b] pyridine skeleton was reported via a multicomponent reaction of thiochromanone with dimethylformamide-dimethylacetal and ethyl acetoacetate in the presence of ammonium acetate.³⁸ In continuation to our work which aimed at developing new synthetic routes for new heterocyclic compounds,³⁹⁻⁴⁷ herein the Q-tube reactor was used in this study. In comparison with conventional heating, the Q-tube reactor has several characteristics and features⁴⁸⁻ including (1) better yield and performance, (2) a cleaner product profile that means light color and less impurities and byproducts, (3) energy savings, lower reaction time, and higher reproducibility, and (4) cheaper and safer because the sealing and pressing are easy. Such promising unique features have encouraged us to utilize the Q-tube in our research to explore the impact of the high pressure on the reaction profile conducted in this study that aimed at synthesizing two very

significant classes of compounds, namely, thiochromeno[4,3b]pyridine and chromeno[4,3-b]pyridine derivatives.

RESULTS AND DISCUSSION

In an effort to develop a new greener strategy for synthesizing distinctive classes of thiochromeno [4,3-b] pyridine and chromeno[4,3-b]pyridine derivatives, we report herein an ammonium acetate-induced Q-tube-assisted system that efficiently provides these targeted compounds from easily obtainable precursors: 3-oxo-2-arylhydrazonopropanals and the heterobenzocyclic ketones (thiochroman-4-one and chroman-4-one) in a single-step reaction (Scheme 1). Our research began with an investigation of the reaction between the thiochroman-4-one (1a) and 2-[2-(2-chloro-5-nitrophenyl)hydrazineylidene]-3-oxo-3-phenylpropanal (2a) as a model reaction (Table 1). Initially, it was observed that refluxing an equimolar mixture of thiochroman-4-one (1a) and arylhydrazonal 2a in the presence of two equivalents of ammonium acetate in different solvents, such as dioxane, dimethylformamide (DMF), acetonitrile, ethanol, or propanol at atmospheric pressure for 18 h, did not give any products (Table 1, entries

Article



Figure 2. X-ray plot of single crystallographic data collected for 4s.

1-5). However, conducting this model reaction in acetic acid as a solvent at reflux for 6 h afforded a product identified as 3-[(2-chloro-5-nitrophenyl)diazenyl]-2-phenyl-5Hthiochromeno[4,3-b]pyridine (4a) in 45% yield (Table 1, entry 6), but not the acyclic product 3 based on its spectroscopic data (Scheme 1). For example, the mass spectrometry (MS) and high-resolution MS (HRMS) spectrometric analyses of 4a showed a molecular ion peak at 458 and an exact mass of m/z 458.0599 in complete agreement with the molecular composition of C24H15ClN4O2S corresponding to 4a. The ¹H NMR spectrum of 4a in TFA-d revealed a set of resonance peaks in the region of 7.32-8.22 ppm due to 13 aromatic protons in addition to two singlet signals at 8.76 and 4.08 ppm corresponding to the pyridine H-4 and CH_2 protons, respectively. Moreover, the ¹³C NMR spectra of 4a showed 22 signals and were free of any C=O signals. The skeletal structure of this class of compounds was also confirmed by obtaining an X-ray single crystal structure of one member of this family, as shown in Figure 2.

The obtained results encouraged us to investigate the factors influencing the optimization of this reaction in order to synthesize the target compounds in a sustainable and green manner, as well as to highlight the benefits of the Q-tube pressure reactor as an affordable, cost-effective alternative to the expensive microwave reactor. Because of its simple sealing and pressure release features, the Q-tube pressure reactor enables a specific chemical reaction to be carried out safely under high pressure. This eliminates inadvertent explosions caused by abrupt increases in pressure when using a typical sealed-pressure tube. Thus, for comparison purposes, we carried out the abovementioned model reaction utilizing the Q-tube reactor by mixing equimolar amounts of thiochroman-4-one (1a) and arylhydrazonal 2a and double equivalents of ammonium acetate in acetic acid using a 35 mL borosilicateglass tube of the high-pressure Q-tube reactor with heating at 160 °C for 45 min to produce the same product 4a in better yield (86%) (Table 1, entry 8). It is worthy to mention that doubling the quantities of the reactants also provided 4a in a

very comparable yield. Elongation of the reaction time did not improve the reaction yield. After the clear emphasis on the efficiency of Q-tube and acetic acid-ammonium acetate buffer system to conduct the targeted reaction (Table 1, entries 7– 10), we studied the effect of temperature on the reaction course where temperature plays a vital role in determining the efficacy of reactions. Therefore, when the reaction was performed at 155 °C, the reaction yield was found to be 82% (Table 1, entry 7), and upon increasing the temperature to 165 °C and then to 170 °C, compound 4a was obtained in 91 and 93% yields, respectively (Table 1, entries 9 and 10). Thus, the best temperature for conducting this reaction was 170 °C.

For diversity, further investigations have been conducted to assess the scope and limitations of the above reaction under the optimum condition obtained from the model experiment (entry 10, Table 1). For this target, an assortment of arylhydrazonals 2b-g was synthesized to carry out their reactions with (thio)chroman-4-ones 1a-c. Thus, heating an equimolar mixture of (thio)chroman-4-ones 1a,b and arylhydrazonals 2 in the presence of a double equivalent of ammonium acetate in acetic acid at high pressure by using Q-tube at 170 °C led to the formation of the corresponding (thio)chromeno[4,3-b]pyridine derivatives 4. During this study, it was observed that the nature of substituents on the N-aryl moiety of the arylhydrazonals has an influence on the reaction yields, where arylhydrazonals having an N-aryl moiety substituted with two electron-withdrawal substituents such as halogens (Cl and Br) and NO₂ provided the corresponding thiochromeno[4,3-b]pyridine products in excellent yields (Table 2). While for N-aryl moieties having one electronwithdrawal substituent (such as Cl or Br), the desired thiochromeno[4,3-b]pyridine derivatives were produced in a little bit lower yields. Furthermore, reaction of the arylhydrazonals 2 with the 6-chlorothiochroman-4-one 1c afforded the corresponding thiochromeno[4,3-b]pyridine derivatives in very high yields (Table 2, entries 2,5,8,11, and 18). The exact structure of the chromeno[4,3-b]pyridine products and their

Table 2. Reactions of (Thio)chroman-4-ones 1a-c with Arylhydrazonals 2a-g Using Q-Tube^a

			R Art Art	CHO N N Ar ₂	cOH/AcONH₄→	R	Ar_1 $N \approx N \approx Ar_2$ X	2	
			1a-c	2a-g	45 min	4	la-s		
Entry	Ar ₁	Ar ₂	Product	Yield (%) ^b	Entry	Ar ₁	Ar ₂	Product Çi	Yield (%) ^b
1	Ph	2-Cl-5-NO ₂ -Ph		93	11	4-Cl-Ph	4-Cl-Ph		85
2	Ph	2-Cl-5-NO ₂ -Ph		89	12	4-Cl-Ph	4-Cl-Ph		87
3	Ph	2-Cl-5-NO ₂ -Ph		91					
4	4-Cl-Ph	2-Cl-5-NO2-Ph		94	13	4-Cl-Ph	4-Cl-3-NO2-Ph		94
5	4-Cl-Ph	2-Cl-5-NO ₂ -Ph		93	14	4-Cl-Ph	4-Cl-3-NO2-Ph		91
6	4-Cl-Ph	2-Cl-5-NO2-Ph		90	15	4-F-Ph	3-Br-Ph	$ \begin{array}{c} F \\ N \\ N \\ S \\ 4\circ \end{array} $	85
7	4-Br-Ph	2-Cl-5-NO2-Ph	$ \begin{array}{c} Br \\ N \\ N \\ $	95	16	4-F-Ph	3-Br-Ph	P N N N N N N N N N N N N N N N N N	84
8	4-Br-Ph	2-Cl-5-NO ₂ -Ph		91	17	C4H3S	2-Cl-5-NO ₂ -Ph	$S \rightarrow O_2$ $N \rightarrow O_2$ $C \rightarrow C$ $C \rightarrow C$ $C \rightarrow C$	90
9	4-Br-Ph	2-Cl-5-NO ₂ -Ph	$ \begin{array}{c} $	92	18	C4H3S	2-Cl-5-NO ₂ -Ph		88
10	4-Cl-Ph	4-Cl-Ph		88	19	C4H3S	2-Cl-5-NO ₂ -Ph	$ \begin{array}{c} $	90

^aReaction conditions: a mixture of thiochroman-4-one and chroman-4-one (5 mmol), arylhydrazonals (5 mmol), and NH₄OAc (10 mmol) in AcOH (15 mL) was charged in the Q-tube reactor's 35 mL glass tube and heated for 45 min at 170 °C (oil bath). ^bIsolated yield.

regioselectivities were unequivocally confirmed by measuring the X-ray single crystal of an exemplified compound, compound **4s**, as depicted in Figure 2 and Table 3.

Table 3. Some of the Selected Bond Angles and Bond Lengths for 4s

bond	bond length (Å)	bond	bond angle (°)
C1-C2	1.395 (4)	C3-C2-C1	119.8 (3)
C2-C3	1.366 (4)	C5-C10-C11	118.6 (3)
N3-C17	1.417 (3)	C11-N1-C12	118.7 (2)
N2-C1	1.407 (3)	C5-C10-C11	118.6 (3)
N1-C11	1.335 (3)	C1-C12-C13	125.2 (2)
N1-C12	1.330 (3)	N2-N3-C17	114.1 (2)
N2-N3	1.254 (3)	N3-N2-C1	114.3 (2)
C5-O1	1.374 (4)	C18-C19-N4	117.7 (3)
C4-O1	1.437 (4)	C5-O1-C4	116.2 (2)

Scheme 2 depicts the mechanistic approach for this Q-tube cyclocondensation process, which consists of two successive condensation reactions. In this manner, the enol form of thiochroman-4-one or chroman-4-one (1) generated by AcOH-driven enolization was nucleophilically added to the arylhydrazonal aldehyde carbonyl-carbon to create the adduct **A**, which forms the alkylidene intermediate **B** by losing one water molecule. This intermediate was then transformed to the nonisolable intermediate **C** in the presence of ammonium acetate. The NH₂ moiety targeted thiochroman-4-one or chroman-4-one (1) carbonyl carbon in the second nucleophilic addition to generate the adduct **D**, which lost the second water molecule to produce the targeted compound **4**.

CONCLUSIONS

In conclusion, the abovementioned research study developed an efficient high-pressure Q-tube-assisted methodology for synthesizing an unparalleled series of thiochromeno[4,3-b]pyridine and chromeno[4,3-b]pyridine derivatives through ammonium acetate-mediated cyclocondensation reactions of 3oxo-2-arylhydrazonopropanals with thiochroman-4-one and chroman-4-one precursors, respectively, by using the highpressure Q-tube reactor as a secure, efficient, and environmentally benign tool.

EXPERIMENTAL SECTION

General. Melting points were measured using an uncorrected Griffin melting point equipment. KBr discs and a Jasco FTIR-6300 spectrophotometer were used to record IR spectra. On a Bruker DPX 600 superconducting NMR spectrometer, 1H NMR (600 MHz) and 13C NMR (150 MHz) spectra were recorded at 25 °C using TFA-d as the solvent and TMS as an internal standard. Chemical shifts () were reported in parts per million (ppm). A high-resolution gas chromatography (GC)-MS (DFS) thermos spectrometer at 70.1 eV and a magnetic sector mass analyzer were used to record low-resolution electron impact mass spectra [MS (EI)] and high-resolution electron impact mass spectra [HRMS (EI)]. Thin-layer chromatography (TLC) was used to track the progress of the reactions and assess the homogeneity of the products. The reactions were carried out with the help of a Qtube kit from Q Labtech (distributed by Sigma-Aldrich), which included a stainless-steel adapter with a pressure gauge (300 psi), a needle adapter, a borosilicate glass pressure tube (35 mL), a Teflon sleeve, PTFE-faced silicone septa, and a catch bottle. A Bruker X8 Prospector diffractometer was used to acquire X-ray crystallographic data.

Cyclocondensation Reactions between (Thio)chroman-4-ones 1a–c and Arylhydrazonals 4a–s. General Procedure. A mixture of (thio)chroman-4-ones 1a– c (5 mmol), arylhydrazonals 2a-g (5 mmol), NH₄OAc (10 mmol), and glacial AcOH (15 mL) was charged in the glass tube (35 mL) of the Q-tube reactor, and then, a septa was mounted on the top of each tube and the required cap and pressure adapter were utilized. The mixture was heated for 45 min at 170 °C (oil bath). The progress of each reaction was tracked utilizing GC–MS and TLC. After cooling to room temperature, the formed solid products were filtered off, washed with EtOH, and re-crystallized from the proper solvent (as shown below) to provide the thiochromeno[4,3-*b*]pyridine and chromeno[4,3-*b*]pyridine systems as pure products.

Scheme 2. Mechanistic Approach for the Formation of Compound 4



https://doi.org/10.1021/acsomega.1c05347 ACS Omega 2021, 6, 34065-34074

(E)-3-[(2-Chloro-5-nitrophenyl)diazenyl]-2-phenyl-5Hthiochromeno[4,3-b]pyridine (4a). Recrystallized from the EtOH/DMF mixture (1:2) as orange crystals, yield: 2.10 g (93%), m.p. 246–247 °C; IR (KBr): ν/cm^{-1} 1593 (C=N); ¹H NMR (TFA-*d*, 600 MHz): δ 4.08 (s, 2H, CH₂), 7.32 (td, *J* = 7.8, 1.8 Hz, 1H, Ar-H), 7.45-7.50 (m, 2H, Ar-H), 7.54 (t, J = 7.8 Hz, 2H, Ar-H), 7.63 (t, J = 7.8 Hz, 1H, Ar-H), 7.64-7.70 (m, 3H Ar-H), 8.05 (d, J = 7.8 Hz, 1H, Ar-H), 8.17-8.22 (m, 2H, Ar–H), 8.76 (s, 1H, pyridine H-4); ${}^{13}C{}^{1}H{}$ NMR (TFA-d, 150 MHz): δ 31.93 (CH₂), 115.53, 127.53, 129.58, 129.98, 130.45, 130.48, 131.74, 132.28, 133.42, 134.36, 135.19, 135.81, 136.46, 137.65, 143.35, 147.26, 147.85, 149.45, 151.21, 152.39, 156.03; MS (EI): m/z (%) 460 (M⁺ + 2, 26.10), 459 (M⁺+1, 33.08), 458 (M⁺, 63.14), 457 (M⁺ - 1, 45.91). HRMS (EI): m/z calcd for $C_{24}H_{15}ClN_4O_2S$ (M⁺), 458.0599; found, 458.0599.

(E)-9-Chloro-3-[(2-chloro-5-nitrophenyl)diazenyl]-2-phenyl-5H-thiochromeno[4,3-b]pyridine (4b). Recrystallized from the dioxane/DMF mixture (1:1) as orange crystals, yield: 2.17 g (89%), m.p. 249–250 °C; IR (KBr): ν/cm^{-1} 1595 (C=N); ¹H NMR (TFA-d, 600 MHz): δ 4.22 (s, 2H, CH₂), 7.56–7.58 (m, 2H, Ar–H), 7.68 (t, J = 7.8 Hz, 2H, Ar– H), 7.77-7.79 (m, 3H, Ar-H), 7.83 (dd, J = 7.8, 1.2 Hz, 1H, Ar-H), 8.21 (d, J = 1.2 Hz, 1H, Ar-H), 8.34–8.36 (m, 2H Ar-H), 8.90 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFA-d, 150 MHz): δ 32.31 (CH₂), 115.90, 129.04, 129.85, 130.49, 130.55, 132.08, 133.63, 133.77, 134.95, 135.57, 136.82, 137.28, 137.63, 141.94, 147.73, 148.68, 149.82, 151.54, 151.56, 156.88; MS (EI): m/z (%) 494 (M⁺+2, 79.68), 493 (M⁺ + 1, 86.11), 492 (M^+ , 100.00), 491 (M^+ – 1, 85.94). HRMS (EI): *m/z* calcd for C₂₄H₁₄Cl₂N₄O₂S (M⁺), 492.0209; found, 492.0210.

(E)-3-[(2-Chloro-5-nitrophenyl)diazenyl]-2-phenyl-5Hchromeno[4,3-b]pyridine (4c). Recrystallized from the EtOH/ DMF mixture (1:1) as orange crystals, yield: 2.00 g (91%), m.p. 276–277 °C; IR (KBr): ν/cm^{-1} 1589 (C=N); ¹H NMR (TFA-*d*, 600 MHz): δ 5.44 (s, 2H, CH₂), 7.14 (d, J = 8.4 Hz, 1H, Ar-H), 7.20 (t, J = 8.4 Hz, 1H, Ar-H), 7.59-7.63 (m, 3H, Ar-H), 7.68-7.70 (m, 3H Ar-H), 7.74 (d, J = 8.4 Hz, 1H, Ar-H), 8.05 (dd, J = 7.8, 1.8 Hz, 1H, Ar-H), 8.24-8.26 (m, 2H, Ar-H), 8.71 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFA-d, 150 MHz): δ 68.80 (CH₂), 115.34, 115.90, 121.69, 126.77, 126.79, 129.71, 130.22, 131.48, 132.38, 133.15, 133.17, 134.96, 135.64, 141.05, 147.02, 147.50, 149.25, 149.69, 150.97, 156.19, 161.78; MS (EI): m/z (%) 444 (M⁺ + 2, 30.05), 443 $(M^++1, 46.39), 442 (M^+, 94.02), 441 (M^+ - 1, 85.79)$. HRMS (EI): m/z calcd for $C_{24}H_{15}ClN_4O_3$ (M⁺), 442.0827; found, 442.0822.

(*E*)-3-[(2-Chloro-5-nitrophenyl)diazenyl]-2-(4-chlorophenyl)-5H-thiochromeno[4,3-b]pyridine (4d). Recrystallized from the dioxane/DMF mixture (2:1) as orange crystals, yield: 2.30 g (94%), m.p. 253–254 °C; IR (KBr): ν /cm⁻¹ 1595 (C=N); ¹H NMR (TFA-d, 600 MHz): δ 4.42 (s, 2H, CH₂), 7.67 (td, *J* = 7.8, 1.8 Hz, 1H, Ar–H), 7.80–7.86 (m, 4H, Ar–H), 7.96 (d, *J* = 8.4 Hz, 2H, Ar–H), 8.04 (d, *J* = 7.8 Hz, 1H, Ar–H), 8.37 (d, *J* = 7.8 Hz, 1H, Ar–H), 8.53–8.55 (m, 2H, Ar–H), 9.10 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFA-d, 150 MHz): δ 31.99 (CH₂), 115.43, 127.47, 128.78, 129.64, 130.12, 130.47, 132.12, 132.33, 134.45, 134.74, 135.29, 136.85, 137.79, 143.26, 143.50, 147.40, 147.83, 149.44, 151.18, 152.69, 154.81; MS (EI): *m*/*z* (%) 494 (M⁺ + 2, 68.59), 493 (M⁺+1, 73.04), 492 (M⁺, 100.00), 491 (M⁺ – 1, 67.89). HRMS (EI): *m*/*z* calcd for C₂₄H₁₄Cl₂N₄O₂S (M⁺), 492.0209; found, 492.0209.

(E)-9-Chloro-3-[(2-chloro-5-nitrophenyl)diazenyl]-2-(4chlorophenyl)-5H-thiochromeno-[4,3-b]pyridine (4e). Recrystallized from the dioxane/DMF mixture (1:1) as orange crystals, yield: 2.41 g (93%), m.p. 262–263 °C; IR (KBr): $\nu/$ cm^{-1} 1593 (C=N); ¹H NMR (TFA-*d*, 600 MHz): δ 4.15 (s, 2H, CH₂), 7.49–7.50 (m, 2H, Ar–H), 7.59 (d, J = 8.4 Hz, 2H, Ar-H), 7.69 (d, J = 8.4 Hz, 2H, Ar-H), 7.78 (d, J = 9.0 Hz, 1H, Ar-H), 8.14 (d, J = 1.8 Hz, 1H, Ar-H), 8.28-8.31 (m, 2H, Ar-H), 8.84 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFAd, 150 MHz): δ 31.51 (CH₂), 114.97, 127.96, 128.15, 129.07, 129.77, 131.65, 132.82, 134.20, 134.22, 134.80, 136.33, 136.47, 136.90, 141.23, 143.06, 146.99, 147.82, 148.99, 150.69, 150.98, 154.85; MS (EI): m/z (%) 528 (M⁺+2, 98.92), 527 (M⁺ + 1, 86.23), 526 (M⁺, 92.04), 525 (M⁺ - 1, 100.00). HRMS (EI): m/z calcd for $C_{24}H_{13}Cl_3N_4O_2S$ (M⁺), 525.9819; found, 525.9818.

(E)-3-[(2-Chloro-5-nitrophenyl)diazenyl]-2-(4-chlorophenyl)-5H-chromeno[4,3-b]pyridine (4f). Recrystallized from the dioxane/DMF mixture (1:1) as orange crystals, yield: 2.12 g (90%), m.p. 260–261 °C; IR (KBr): ν/cm^{-1} 1590 (C=N); ¹H NMR (TFA-*d*, 600 MHz): δ 5.73 (s, 2H, CH₂), 7.43 (d, *J* = 7.8 Hz, 1H, Ar-H), 7.49 (t, J = 7.8 Hz, 1H, Ar-H), 7.86 (d, J = 8.4 Hz, 2H, Ar-H), 7.91 (t, J = 7.8 Hz, 1H, Ar-H), 7.95 (d, J = 8.4 Hz, 2H, Ar-H), 8.04 (d, J = 9.0 Hz, 1H, Ar-H), 8.33 (dd, I = 7.8, 1.8 Hz, 1H, Ar-H), 8.52-8.55 (m, 2H, Ar-H),9.00 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFA-d, 150 MHz): δ 69.00 (CH₂), 115.42, 116.04, 121.93, 126.98, 127.05, 128.74, 130.00, 132.04, 132.68, 133.74, 134.69, 135.23, 141.40, 143.24, 147.31, 147.66, 149.41, 150.16, 151.12, 155.11, 162.08; MS (EI): m/z (%) 478 (M⁺ + 2, 58.90), 477 $(M^++1, 76.05), 476 (M^+, 94.01), 475 (M^+ - 1, 84.02)$. HRMS (EI): *m/z* calcd for C₂₄H₁₄Cl₂N₄O₃ (M⁺), 476.0437; found, 476.0436.

(E)-2-(4-Bromophenyl)-3-[(2-chloro-5-nitrophenyl)diazenyl]-5H-thiochromeno[4,3-b]pyridine (4g). Recrystallized from the dioxane/DMF mixture (1:1) as orange crystals, yield: 2.50 g (95%), m.p. 248–249 °C; IR (KBr): ν/cm^{-1} 1593 (C=N); ¹H NMR (TFA-d, 600 MHz): δ 4.14 (s, 2H, CH₂), 7.41 (t, *J* = 7.8 Hz, 1H, Ar–H), 7.56–7.61 (m, 4H, Ar– H), 7.73–7.78 (m, 3H, Ar–H), 8.10 (d, *J* = 7.8 Hz, 1H, Ar– H), 8.26–8.28 (m, 2H, Ar–H), 8.83 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFA-d, 150 MHz): δ 31.57 (CH₂), 115.03, 127.02, 128.77, 129.21, 129.69, 130.04, 130.90, 131.90, 133.99, 134.30, 134.77, 134.85, 136.43, 137.37, 143.07, 146.99, 147.35, 149.01, 150.76, 152.28, 154.49; MS (EI): *m/z* (%) 538 (M⁺+2, 100.00), 537 (M⁺ + 1, 77.05), 536 (M⁺, 66.28), 535 (M⁺ – 1, 39.07). HRMS (EI): *m/z* calcd for C₂₄H₁₄BrClN₄O₂S (M⁺), 535.9704; found, 535.9703.

(E)-2-(4-Bromophenyl)-9-chloro-3-[(2-chloro-5nitrophenyl)diazenyl]-5H-thiochromeno-[4,3-b]pyridine (4h). Recrystallized from the dioxane/DMF mixture (1:1) as orange crystals, yield: 2.50 g (91%), m.p. 261–262 °C; IR (KBr): ν /cm⁻¹ 1592 (C=N); ¹H NMR (TFA-d, 600 MHz): δ 4.17 (s, 2H, CH₂), 7.51–7.52 (m, 2H, Ar–H), 7.61 (d, *J* = 9.0 Hz, 2H, Ar–H), 7.76–7.81 (m, 3H, Ar–H), 8.16 (s, 1H, Ar– H), 8.29–8.30 (m, 2H, Ar–H), 8.86 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFA-d, 150 MHz): δ 31.54 (CH₂), 115.00, 128.17, 128.45, 129.09, 129.14, 129.79, 131.06, 132.83, 134.25, 134.73, 134.82, 136.37, 136.48, 136.93, 141.25, 147.02, 147.77, 148.99, 150.71, 151.02, 154.93; MS (EI): *m*/*z* (%) 572 (M⁺+2, 100), 571 (M⁺ + 1, 72.09), 570 (M⁺, 54.78), 569 (M⁺ – 1, 32.05). HRMS (EI): m/z calcd for $C_{24}H_{13}BrCl_2N_4O_2S$ (M⁺), 569.9314; found, 569.9309.

(E)-2-(4-Bromophenyl)-3-[(2-chloro-5-nitrophenyl)diazenyl]-5H-chromeno[4,3-b]pyridine (4i). Recrystallized from the EtOH/DMF mixture (1:1) as orange crystals, yield: 2.37 g (92%), m.p. 252–253 °C; IR (KBr): ν/cm^{-1} 1588 (C= N); ¹H NMR (TFA-*d*, 600 MHz): δ 6.07 (s, 2H, CH₂), 7.79 (d, J = 8.4 Hz, 1H, Ar-H), 7.84 (t, J = 8.4 Hz, 1H, Ar-H),8.21 (d, J = 7.8 Hz, 2H, Ar-H), 8.26 (t, J = 8.4 Hz, 1H, Ar-H), 8.38–8.40 (m, 3H, Ar–H), 8.67 (dd, J = 8.4, 1.8 Hz, 1H, Ar-H), 8.87-8.91 (m, 2H, Ar-H), 9.35 (s, 1H, pyridine H-4); ${}^{13}C{}^{1}H$ NMR (TFA-d, 150 MHz): δ 68.95 (CH₂), 115.38, 115.96, 121.90, 126.95, 126.96, 129.10, 130.00, 131.27, 132.64, 133.70, 134.61, 135.10, 135.20, 141.41, 147.29, 147.57, 149.36, 150.14, 151.07, 155.16, 162.04; MS (EI): m/z (%) 522 $(M^{+} + 2, 97.81), 521 (M^{+} + 1, 100.00), 520 (M^{+}, 72.14), 519$ $(M^+ - 1, 60.98)$. HRMS (EI): m/z calcd for $C_{24}H_{14}BrClN_4O_3$ (M⁺), 519.9932; found 519.9936.

(*E*)-2-(4-Chlorophenyl)-3-[(4-chlorophenyl)diazenyl]-5Hthiochromeno[4,3-b]pyridine (4j). Recrystallized from dioxane as orange crystals, yield: 1.95 g (88%), m.p. 202–203 °C; IR (KBr): ν/cm^{-1} 1591 (C=N); ¹H NMR (TFA-*d*, 600 MHz): δ 4.07 (s, 2H, CH₂), 7.33–7.37 (m, 3H, Ar–H), 7.45– 7.53 (m, 4H, Ar–H), 7.60 (d, *J* = 8.4 Hz, 2H, Ar–H), 7.71 (d, *J* = 7.8 Hz, 2H, Ar–H), 8.01 (d, *J* = 7.8 Hz, 1H, Ar–H), 8.69 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFA-*d*, 150 MHz): δ 31.45 (CH₂), 127.06, 127.34, 128.55, 128.75, 129.90, 131.51, 131.80, 131.99, 133.74, 134.07, 134.10, 136.15, 136.85, 142.39, 142.50, 143.29, 147.92, 150.77, 153.12; MS (EI): *m/z* (%) 449 (M⁺+2, 44.53), 448 (M⁺ + 1, 53.94), 447 (M⁺, 63.09), 446 (M⁺ – 1, 54.61). HRMS (EI): *m/z* calcd for C₂₄H₁₅Cl₂N₃S (M⁺), 447.0358; found, 447.0359.

(E)-9-Chloro-2-(4-chlorophenyl)-3-[(4-chlorophenyl)diazenyl]-5H-thiochromeno[4,3-b]pyridine (4k). Recrystallized from the dioxane/DMF mixture (2:1) as orange crystals, yield: 2.00 g (85%), m.p. 191–192 °C; IR (KBr): ν/cm^{-1} 1593 (C=N); ¹H NMR (TFA-d, 400 MHz): δ 4.17 (s, 2H, CH₂), 7.42–7.47 (m, 2H, Ar–H), 7.60 (d, *J* = 8.4 Hz, 2H, Ar–H), 7.69 (d, *J* = 8.4 Hz, 2H, Ar–H), 7.75 (d, *J* = 8.4 Hz, 2H, Ar–H), 7.93 (d, *J* = 8.4 Hz, 2H, Ar–H), 8.14 (s, 1H, Ar– H), 8.79 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFA-d, 150 MHz): δ 31.42 (CH₂), 127.34, 127.67, 128.70, 130.83, 131.44, 131.97, 132.23, 132.61, 134.01, 134.09, 134.87, 136.11, 136.43, 140.58, 142.62, 143.49, 148.39, 149.49, 153.09; MS (EI): *m*/*z* (%) 483 (M⁺ + 2, 91.97), 482 (M⁺ + 1, 100.00), 481 (M⁺, 87.12), 480 (M⁺ – 1, 75.68). HRMS (EI): *m*/*z* calcd for C₂₄H₁₄Cl₃N₃S (M⁺), 480.9969; found, 480.9952.

(*E*)-2-(4-Chlorophenyl)-3-[(4-chlorophenyl)diazenyl]-5Hchromeno[4,3-b]pyridine (4l). Recrystallized from dioxane as orange crystals, yield: 1.85 g (87%), m.p. 228–229 °C; IR (KBr): ν/cm^{-1} 1591 (C=N); ¹H NMR (TFA-*d*, 600 MHz): δ 6.10 (s, 2H, CH₂), 9.33 (d, *J* = 7.8 Hz, 1H, Ar–H), 9.39 (t, *J* = 7.8 Hz, 1H, Ar–H), 9.57 (d, *J* = 8.4 Hz, 2H, Ar–H), 9.75 (d, *J* = 8.4 Hz, 2H, Ar–H), 9.78–9.81 (m, 3H, Ar–H), 9.90 (d, *J* = 9.0 Hz, 2H, Ar–H), 10.17 (d, *J* = 7.8 Hz, 1H, Ar–H), 10.81 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFA-*d*, 150 MHz): δ 69.41 (CH₂), 116.57, 122.26, 127.06, 127.31, 128.22, 129.51, 132.35, 132.83, 133.00, 133.98, 134.99, 141.21, 143.22, 143.82, 148.67, 149.11, 153.97, 154.19, 161.97; MS (EI): *m/z* (%) 433 (M⁺ + 2, 34.96), 432 (M⁺ + 1, 50.04), 431 (M⁺, 51.23), 430 (M⁺ - 1, 58.12). HRMS (EI): *m/z* calcd for C₂₄H₁₅Cl₂N₃O (M⁺), 431.0587; found, 431.0584.

(E)-3-[(4-Chloro-3-nitrophenyl)diazenyl]-2-(4-chlorophenyl)-5H-thiochromeno[4,3-b]pyridine (4m). Recrystallized from the dioxane/DMF mixture (2:1) as orange crystals, yield: 2.30 g (94%), m.p. 214–215 °C; IR (KBr): ν/cm^{-1} 1594 (C=N); ¹H NMR (TFA-*d*, 600 MHz): δ 4.70 (s, 2H, CH_2), 8.07–7.13 (m, 3H, Ar–H), 8.16 (d, I = 8.4 Hz, 2H, Ar-H), 8.21-8.26 (m, 2H, Ar-H), 8.35 (d, J = 8.4 Hz, 2H, Ar-H), 8.63 (d, I = 8.4 Hz, 1H, Ar-H), 8.93 (d, I = 2.4 Hz, 1H, Ar–H), 9.35 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFAd, 150 MHz): δ 31.49 (CH2), 115.78, 127.96, 128.97, 130.04, 130.85, 131.52, 131.75, 133.38, 133.66, 133.96, 134.13, 135.70, 136.30, 137.36, 142.95, 142.95, 147.33, 150.63, 151.92, 152.92, 154.08; MS (EI): m/z (%) 494 (M⁺ + 2, 68.61), 493 (M⁺ + 1, 71.18), 492 (M^+ , 100.00), 491 ($M^+ - 1$, 65.90). HRMS (EI): m/z calcd for C₂₄H₁₄Cl₂N₄O₂S (M⁺), 492.0209; found, 492.0209.

(E)-3-[(4-Chloro-3-nitrophenyl)diazenyl]-2-(4-chlorophenyl)-5H-chromeno[4,3-b]pyridine (4n). Recrystallized from the dioxane/DMF mixture (1:1) as orange crystals, yield: 2.15 g (91%), m.p. 241–242 °C; IR (KBr): ν/cm^{-1} 1591 (C=N); ¹H NMR (TFA-*d*, 600 MHz): δ 5.46 (s, 2H, CH₂), 7.17 (d, *J* = 7.8 Hz, 1H, Ar–H), 7.23 (t, J = 7.8 Hz, 1H, Ar–H), 7.58 (d, J = 8.4 Hz, 2H, Ar-H), 7.63-766 (m, 3H, Ar-H), 7.69 (d, J = 8.4 Hz, 1H, Ar–H), 8.00 (dd, J = 8.4, 1.8 Hz, 1H, Ar–H), 8.06 (d, J = 7.8 Hz, 1H, Ar-H), 8.32 (d, J = 1.2 Hz, 1H, Ar-H),8.70 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFA-d, 150 MHz): δ 68.74 (CH₂), 115.81, 121.68, 123.11, 126.74, 128.54, 130.37, 131.78, 132.12, 133.44, 134.38, 134.83, 135.81, 141.04, 142.97, 147.35, 149.60, 150.72, 153.09, 154.55, 161.72, 164.78; MS (EI): m/z (%) 478 (M⁺ + 2, 61.04), 477 (M⁺ + 1, 85.97), 476 (M⁺, 100.00), 475 (M⁺ - 1, 96.07). HRMS (EI): m/z calcd for $C_{24}H_{14}Cl_2N_4O_3$ (M⁺) 476.0437, found 476.0431.

(E)-3-[(3-Bromophenyl)diazenyl]-2-(4-fluorophenyl)-5Hthiochromeno[4,3-b]pyridine (40). Recrystallized from dioxane as orange crystals, yield: 2.00 g (85%), m.p. 212-213 °C; IR (KBr): ν/cm^{-1} 1590 (C=N); ¹H NMR (TFA-d, 600 MHz): δ 5.10 (s, 2H, CH₂), 7.24–7.33 (m, 3H, Ar–H), 7.38 (t, J = 7.6 Hz, 1H, Ar-H), 7.49-7.60 (m, 3H, Ar-H), 7.70-7.73 (m, 2H, Ar-H), 7.77 (d, J = 8.0 Hz, 1H, Ar-H), 7.88 (s, 1H, Ar-H), 8.05 (d, J = 8.0 Hz, 1H, Ar-H), 8.70 (s, 1H, pyridine H-4); ${}^{13}C{}^{1}H{}$ NMR (TFA-*d*, 150 MHz): δ 31.45 (CH_2) , (118.45, 118.67) $(d^2, J_{CF} = 22.0 \text{ Hz})$, 125.59, 125.94, (126.26, 126.29) (d⁴, $J_{CF} = 3.0$ Hz), 127.07, 128.04, 128.83, 129.93, 131.83, 132.88, 133.72, (135.37, 135.46) $(d^3, J_{CF} = 9.0)$ Hz), 135.98, 136.92, 138.81, 142.47, 147.69, 150.99, 153.52, 155.49, (167.00, 169.54) (d¹, J_{CF} = 254.0 Hz); MS (EI): m/z(%) 477 (M^+ + 2, 96.03), 476 (M^+ + 1, 100.00), 475 (M^+ , 90.15), 474 (M⁺ - 1, 69.34). HRMS (EI): m/z calcd for C₂₄H₁₅BrFN₃S (M⁺), 475.0149; found, 475.0147.

(E)-3-[(3-Bromophenyl)diazenyl]-2-(4-fluorophenyl)-5Hchromeno[4,3-b]pyridine (**4p**). Recrystallized from dioxane as orange crystals, yield: 1.90 g (84%), m.p. 229–230 °C; IR (KBr): ν/cm^{-1} 1593 (C==N); ¹H NMR (TFA-*d*, 600 MHz): δ 5.40 (s, 2H, CH₂), 7.14 (d, *J* = 8.4 Hz, 1H, Ar–H), 7.19 (t, *J* = 8.4 Hz, 1H, Ar–H), 7.25–7.27 (m, 2H, Ar–H), 7.30 (t, *J* = 7.8 Hz, 1H, Ar–H), 7.58–7.61 (m, 2H, Ar–H), 7.69–7.71 (m, 2H, Ar–H), 7.75 (d, *J* = 8.4 Hz, 1H, Ar–H), 7.85 (t, *J* = 1.8 Hz, 1H, Ar–H), 8.00 (dd, *J* = 8.4, 1.8 Hz, 1H, Ar–H), 8.60 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFA-*d*, 150 MHz): δ 68.48 (CH₂), 115.64, (118.38, 118.53) (d², *J*_{CF} = 22.5 Hz), 121.34, 125.54, 125.83, 126.20, 126.23, 126.27, 126.41, 127.97, 132.00, (132.81, 132.83) (d⁴, *J*_{CF} = 3.0 Hz), (135.33, 135.39) (d³, $J_{CF} = 9.0$ Hz), 138.70, 140.34, 147.54, 148.38, 153.73, 155.40, 161.12, (167.39, 169.10) (d¹, $J_{CF} = 256.5$ Hz); MS (EI): m/z (%) 461 (M⁺ + 2, 69.12), 460 (M⁺ + 1, 100.00), 459 (M⁺, 70.08), 458 (M⁺ - 1, 80.26). HRMS (EI): m/z calcd for $C_{24}H_{15}BrFN_{3}O$ (M⁺), 459.0377; found, 459.0377.

(E)-3-[(2-Chloro-5-nitrophenyl)diazenyl]-2-(thiophen-2-yl)-5H-thiochromeno[4,3-b]pyridine (4q). Recrystallized from dioxane as deep orange crystals, yield: 2.10 g (90%), m.p. 238–239 °C; IR (KBr): ν/cm^{-1} 1619 (C=N); ¹H NMR (TFA-d, 600 MHz): δ 4.10 (s, 2H, CH₂), 7.35 (t, *J* = 5.6 Hz, 1H, Ar-H), 7.46 (t, *J* = 7.2 Hz, 1H, Ar-H), 7.56–7.58 (m, 2H, Ar-H), 7.82 (d, *J* = 7.2 Hz, 1H, Ar-H), 8.05–8.14 (m, 4H, Ar-H), 8.35 (d, *J* = 7.2 Hz, 1H, Ar-H), 8.76 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFA-d, 150 MHz): δ 31.19, 126.89, 128.84, 129.76, 129.99, 130.24, 130.75, 131.90, 133.45, 134.26, 134.85, 135.31, 137.30, 137.74, 141.38, 143.05, 145.37, 147.24, 148.26, 149.14, 150.84, 151.73; MS (EI): m/z (%) 466 (M⁺+2, 40.21), 465 (M⁺ + 1, 41.16), 464 (M⁺, 100.00), 463 (M⁺ - 1, 47.05); HRMS (EI): m/z calcd for C₂₂H₁₃O₂N₄ClS₂ (M⁺), 464.0163; found ,464.0166.

(E)-9-Chloro-3-[(2-chloro-5-nitrophenyl)diazenyl]-2-(thiophen-2-yl)-5H-thiochromeno[4,3-b]pyridine (4r). Recrystallized from dioxane as deep orange crystals, yield: 2.15 g (88%), m.p. 250–251 °C; IR (KBr): ν/cm^{-1} 1616 (C=N); ¹H NMR (TFA-d, 600 MHz): δ 4.11 (s, 2H, CH₂), 7.34 (t, J = 4.8 Hz, 1H, Ar-H), 7.51-7.52 (m, 2H, Ar-H), 7.82 (d, J = 8.4 Hz, 1H, Ar–H), 8.06 (d, J = 4.8 Hz, 1H, Ar–H), 8.13 (s, 1H, Ar– H), 8.17 (d, J = 4.8 Hz, 1H, Ar–H), 8.36 (dd, J = 9.0, 2.4 Hz, 1H, Ar-H), 8.74 (d, J = 3.0 Hz, 1H, Ar-H),, 8.77 (s, 1H, pyridine H-4); ¹³C{¹H} NMR (TFA-*d*, 150 MHz): δ 31.39, 128.26, 128.95, 129.69, 130.00, 130.89, 133.02, 133.85, 134.51, 135.01, 135.93, 136.58, 137.02, 141.42, 141.69, 146.04, 147.46, 148.90, 149.29, 150.71, 150.99; MS (EI): m/z (%) 500 (M⁺ + 2, 71.98), 499 (M⁺ + 1, 63.01), 498 (M⁺, 100.00), 497 (M⁺ -1, 53.21); HRMS (EI): m/z calcd for $C_{22}H_{12}Cl_2N_4O_2S_2$ (M⁺), 497.9773; found, 497.9776.

(E)-3-[(2-Chloro-5-nitrophenyl)diazenyl]-2-(thiophen-2yl)-5H-chromeno[4,3-b]pyridine (4s). Recrystallized from dioxane as orange crystals, yield: 2.00 g (90%), m.p. 269-270 °C; IR (KBr): v/cm⁻¹ 1610 (C=N); ¹H NMR (TFA-d, 600 MHz): δ 5.42 (s, 2H, CH₂), 7.18 (d, J = 8.4 Hz, 1H, Ar-H), 7.28 (t, J = 8.4 Hz, 1H, Ar-H), 7.37 (d, J = 5.4 Hz, 1H, Ar-H), 7.68 (t, J = 8.4 Hz, 1H, Ar-H), 7.84 (d, J = 8.4 Hz, 1H, Ar-H), 8.07-8.09 (m, 2H, Ar-H), 8.13 (d, J = 5.4 Hz, 1H, Ar-H), 8.37 (d, I = 8.4 Hz, 1H, Ar-H), 8.68 (s, 1H, pyridine H-4), 8.77 (d, J = 2.4 Hz, 1H, Ar-H); ¹³C{¹H} NMR (TFA-d, 150 MHz): δ 68.25, 115.29, 121.36, 126.21, 126.34, 129.57, 129.62, 130.53, 131.55, 134.71, 135.32, 140.80, 141.38, 145.13, 147.09, 148.44, 148.99, 149.14, 150.70, 152.25, 152.57, 161.46; MS (EI): m/z (%) 450 (M⁺+2, 37.12), 449 (M⁺ + 1, 44.09), 448 (M⁺, 95.18), 447 (M⁺ – 1, 57.32); HRMS (EI): m/z calcd for C₂₂H₁₃O₃N₄ClS (M⁺), 448.0391; found, 448.0391. Crystal Data, moiety formula: C₂₂H₁₃O₃N₄ClS, M = 448.87, monoclinic, *a* = 7.4390(4) Å, *b* = 25.3934(11) Å, *c* = 10.4929(4) Å, V = 1962.88(16) Å³, $\alpha = \gamma = 90^{\circ}$, $\beta = 97.990(3)$ °, space group: $P2_1/c$ (#14), Z = 4, D_{calc} = 1.519 g·cm⁻³, No. of reflection measured: 3296, unique: 2483, $\theta_{\text{max}} = 66.06^{\circ}$, R1 = 0.0578 (CCDC 2110964).⁵⁶

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsomega.1c05347.

MS, HRMS, ¹H NMR, and ¹³C NMR spectra for the reported compounds (PDF) Crystallographic data for compound **4s** (CIF)

AUTHOR INFORMATION

Corresponding Authors

- Haider Behbehani Chemistry Department, Faculty of Science, Kuwait University, Safat 13060, Kuwait; Phone: +965-55888646; Email: drhaider.b@gmail.com; Fax: +965-248-164-82
- Hamada Mohamed Ibrahim Chemistry Department, Faculty of Science, Kuwait University, Safat 13060, Kuwait; Chemistry Department, Faculty of Science, Fayoum University, Fayoum 63514, Egypt; orcid.org/0000-0001-8355-2676; Phone: +2-01141145768; Email: hmi00@ fayoum.edu.eg, hamadaaldeb@yahoo.com

Authors

Kamal M. Dawood – Chemistry Department, Faculty of Science, Cairo University, Giza 12613, Egypt

Fatemah A. Aryan – College of Basic Education, Science Department, Public Authority of Applied Education and Training, Safat 13092, Kuwait

Complete contact information is available at: https://pubs.acs.org/10.1021/acsomega.1c05347

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Financial support for this study was provided by the Kuwait Foundation for the Advancement of Sciences (KFAS) through a research grant (PR18-14SC-03). The facilities of Analab/SAF supported by research grants GS01/01, GS01/05, GS01/03, and GS03/08 are gratefully acknowledged.

REFERENCES

(1) Nohara, A.; Sugihara, H.; Ukawa, K. 1-Azaxanthone-3-carboxylic acids; DE 2809720 A1, 1978.

(2) Makino, H.; Saijo, T.; Ashida, Y.; Kuriki, H.; Maki, Y. Mechanism of action of an antiallergic agent: Amlexanox (AA-673), in inhibiting histamine release from mast cells. *Int. Arch. Allergy Immunol.* **1987**, *82*, 66–71.

(3) Akyol-Salman, I.; Leçe-Sertöz, D.; Baykal, O. Topical pranoprofen 0.1% is as effective anti-inflammatory and analgesic agent as diclofenac sodium 0.1% after strabismus surgery. *J. Ocul. Pharmacol. Therapeut.* 2007, 23, 280–283.

(4) Núñez-Vergara, L. J.; Squella, J. A.; Navarrete-Encina, P. A.; Vicente-García, E.; Preciado, S.; Lavilla, R. Chromenopyridines: promising scaffolds for medicinal and biological chemistry. *Curr. Med. Chem.* **2011**, *18*, 4761–4785.

(5) Magar, T. B. T.; Seo, S. H.; Kadayat, T. M.; Jo, H.; Shrestha, A.; Bist, G.; Katila, P.; Kwon, Y.; Lee, E.-S. Synthesis and SAR study of new hydroxy and chloro-substituted 2,4-diphenyl-5*H*-chromeno[4,3-*b*]pyridines as selective topoisomerase IIa-targeting anticancer agents. *Bioorg. Med. Chem.* **2018**, *26*, 1909–1919.

(6) Kwon, H.-B.; Park, C.; Jeon, K.-H.; Lee, E.; Park, S.-E.; Jun, K.-Y.; Kadayat, T. M.; Thapa, P.; Karki, R.; Na, Y.; Park, M. S.; Rho, S. B.; Lee, E.-S.; Kwon, Y. A Series of novel terpyridine-skeleton molecule derivants inhibit tumor growth and metastasis by targeting topoisomerases. *J. Med. Chem.* **2015**, *58*, 1100–1122.

(7) Thapa, P.; Jun, K.-Y.; Kadayat, T. M.; Park, C.; Zheng, Z.; Thapa Magar, T. B.; Bist, G.; Shrestha, A.; Na, Y.; Kwon, Y.; Lee, E.-S. Design and synthesis of conformationally constrained hydroxylated 4-phenyl-2-arylchromenopyridines as novel and selective topoisomerase

II-targeted antiproliferative agents. *Bioorg. Med. Chem.* 2015, 23, 6454–6466.

(8) Thapa, P.; Lee, E.-S. 2,4-Diaryl-5*H*-chromeno[4,3-*b*]pyridines: Synthesis, topoisomerase I and II inhibitory activity, and cytotoxicity. *Bull. Korean Chem. Soc.* **2012**, *33*, 3103–3106.

(9) Thapa, U.; Thapa, P.; Karki, R.; Yun, M.; Choi, J. H.; Jahng, Y.; Lee, E.; Jeon, K.-H.; Na, Y.; Ha, E.-M.; Cho, W.-J.; Kwon, Y.; Lee, E.-S. Synthesis of 2,4-diarylchromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structureactivity relationship. *Eur. J. Med. Chem.* **2011**, *46*, 3201–3209.

(10) Gebhardt, P.; Dornberger, K.; Gollmick, F. A.; Gräfe, U.; Härtl, A.; Görls, H.; Schlegel, B.; Hertweck, C. Quercinol, an antiinflammatory chromene from the wood-rotting fungus Daedalea uercina (Oak Mazegill). *Bioorg. Med. Chem. Lett.* **200**7, *17*, 2558– 2560.

(11) Helal, M. H.; Ali, G. A. M. E.-H.; Ali, A. A.; Ammar, Y. A. Onestep synthesis of chromene-3-carboxamide, bischromene, chromeno-[3,4-c]pyridine and bischromeno[3,4-c]pyridine derivatives for antimicrobial evaluation. *J. Chem. Res.* **2010**, *34*, 465–469.

(12) Farag, A. A. N-(Furan-2-ylmethyl)cyanoacetamide in heterocyclic synthesis: synthesis of novel antimicrobial agents encompassing furan, pyridine, chromene, and chromenopyridine moieties. *Der Pharma Chem.* **2015**, *7*, 130–141.

(13) Patil, R.; Ghosh, A.; Sun Cao, P.; Sommer, R. D.; Grice, K. A.; Waris, G.; Patil, S. Novel 5-arylthio-5*H*-chromenopyridines as a new class of anti-fibrotic agents. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 1129–1135.

(14) Vu, A. T.; Campbell, A. N.; Harris, H. A.; Unwalla, R. J.; Manas, E. S.; Mewshaw, R. E. ER β ligands. Part 6: 6H-Chromeno-[4,3-b]quinolines as a new series of estrogen receptor β -selective ligands. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 4053–4056.

(15) Cheng, J.-F.; Ishikawa, A.; Ono, Y.; Arrhenius, T.; Nadzan, A. Novel chromene derivatives as TNF- α inhibitors. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 3647–3650.

(16) Chen, H.; Huang, M.; Li, X.; Liu, L.; Chen, B.; Wang, J.; Lin, Y. first naturally occurring new chromenopyridines from mangrove entophytic fungus Phomopsis sp. 33#. *Fitoterapia* **2018**, *124*, 103–107.

(17) (a) Sosnovskikh, V. Y. Synthesis and properties of 2,3heteroannulated thiochromones-hetero analogs of thioxanthone. *Chem. Heterocycl. Compd.* **2019**, *55*, 103–125. (b) Yu, L.; Chi, J.; Xiao, L.; Li, J.; Tang, Z.; Tan, S.; Li, P. Novel thiochromanone derivatives containing a sulfonyl hydrazone moiety: design, synthesis, and bioactivity evaluation. *Molecules* **2021**, *26*, 2925.

(18) (a) Farghaly, T. A.; Abdallah, M. A.; Khedr, M. A.; Mahmoud, H. K. Synthesis, antimicrobial activity and molecular docking study of thiazole derivatives. *J. Heterocycl. Chem.* **2017**, *54*, 2417–2425. (b) Xiao, L.; Yu, L.; Li, P.; Chi, J.; Tang, Z.; Li, J.; Tan, S.; Wang, X. Design, synthesis, and bioactivity evaluation of new thiochromanone derivatives containing a carboxamide moiety. *Molecules* **2021**, *26*, 4391.

(19) Suresh, L.; Sagar Vijay Kumar, P.; Poornachandra, Y.; Ganesh Kumar, C.; Babu, N. J.; Chandramouli, G. V. P. An expeditious fourcomponent domino protocol for the synthesis of novel thiazolo[3,2a]thiochromeno[4,3-d]pyrimidine derivatives as antibacterial and antibiofilm agents. *Bioorg. Med. Chem.* **2016**, *24*, 3808–3817.

(20) Khan, M. N.; Khan, M. A.; Munawar, M. A. Synthesis and biological evaluation of benzylideneamino-5*H*-thiochromeno[2,3-*b*]-pyridin-5-one. *Lat. Am. J. Pharm.* **2011**, *30*, 980–984.

(21) Sun, X.; Feng, J.; Li, S.; Feng, S.; Liu, Z.; Song, Y.; Qiao, X. Design, synthesis, and antifungal activity of novel thiochromanone derivatives containing 1,3,4-oxadiazole skeleton. *Chin. J. Org. Chem.* **2019**, *39*, 1037–1043.

(22) Li, S.-B.; Qi, H.; Zhang, C.-C.; Liu, Z.-M.; Song, Y.-L.; Qiao, X.-Q. Synthesis, antifungal activity and molecular docking of (E)-3-(((1,3,4-thiadiazol-2-yl)amino)methylene)-thiochroman-4-ones. *Acta Pharm. Sin.* **2018**, *53*, 1518–1525.

(23) Zhang, D.; Ji, X.; Gao, R.; Wang, H.; Meng, S.; Zhong, Z.; Li, Y.; Jiang, J.; Li, Z. Synthesis and antiviral activities of a novel class of thioflavone and flavonoid analogues. Acta Pharm. Sin. B 2012, 2, 575-580.

(24) Krapcho, A. P.; Haydar, S. N.; Truong-Chiott, S.; Hacker, M. P.; Menta, E.; Beggiolin, G. Synthesis and antitumor activities of 5-methyl-1- and 2-[[2-dimethylaminoethyl]amino]-aza-thiopyranoindazoles. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 305–308.

(25) Demirayak, S.; Yurttas, L.; Gundogdu-Karaburun, N.; Karaburun, A. C.; Kayagil, I. New chroman-4-one/thiochroman-4-one derivatives as potential anticancer agents. *Saudi Pharm. J.* **2017**, 25, 1063–1072.

(26) Ichiro, N.; Mitsuru, S.; Masashi, S.; Kazuyoshi, K. Preparation of 4-(6-thiochromancarbonyl)pyrazole derivatives as herbicides. WO 9401431, Jan 20, 1994.

(27) Szucs, S. S. Thiono-thiochroman and -dihydrobenzothiophene compounds as herbicidal agents. WO 2001029033 A2, April 26, 2001.

(28) Steiner, G.; Schmidt, T.; Kordes, M.; Von Deyn, W.; Hofmann, M.; Baumann, E.; Puhl, M.; Heffernan, G.; Culbertson, D. L.; Treacy, M. F. Amino-Substituted benzo(hetero)cyclic derivatives, particularly 1-alkyl-4-benzo(hetero)cyclicsubstituted piperazines, useful as insecticides, acaricides, and nematocides, and their preparation, uses, and Compositions. WO 2004080170, Sept 23, 2004.

(29) Keskin, S.; Balci, M. Intramolecular heterocyclization of opropargylated aromatic hydroxyaldehydes as an expedient route to substituted chromenopyridines under metal-free conditions. *Org. Lett.* **2015**, *17*, 964–967.

(30) Palacios, F.; Alonso, C.; Amezua, P.; Rubiales, G. Synthesis of aza polycyclic compounds derived from pyrrolidine, indolizidine, and indole via intramolecular Diels-Alder cycloadditions of neutral 2-azadienes. J. Org. Chem. **2002**, *67*, 1941–1946.

(31) Taylor, E. C.; French, L. G. Intramolecular Diels-Alder reactions of 1,2,4-triazines: synthesis of tricyclic condensed pyridines and pyrazines. *Tetrahedron Lett.* **1986**, *27*, 1967–1970.

(32) Reinhard, E. J.; Kolodziej, S. A.; Anderson, D. R.; Stehle, N. W.; Vernier, W. F.; Lee, L. F.; Hegde, S. G. Preparation of aminocyanopyridines. particular tricyclic derivatives, as inhibitors of mitogen activated protein kinase-activated protein kinase-2 for treating TNFa mediated diseases. U.S. Patent 20,040,127,519 A1, 2004.

(33) Anderson, D. R.; Vernier, W. F.; Lee, L. F.; Reinhard, E. J.; Hegde, S. G. Tricyclic aminocyanopyridine derivatives, particularly 2amino-3-cyano-5H-chromeno[2,3-b]pyridine derivatives, useful as inhibitors of mitogen activated protein kinase-activated protein kinase-2 (MAPKAP kinase-2, or MK-2), and their pharmaceutical compositions. WO 2004054504 A2, 2004

(34) Wen, L.; Ji, C.; Li, Y.; Li, M. Application of b-(2-Chloroaroyl)thioacetanilide in Synthesis(III): An Efficient Three-Component Synthesis of Thiochromeno[2,3-b]pyridines Catalyzed by KF/Neutral Al_2O_3 Co-operated with PEG 6000 under Microwave Irradiation. J. Comb. Chem. 2009, 11, 799–805.

(35) Wen, L.-R.; Ji, C.; Li, M.; Xie, H.-Y. Application of orthochloro-aroylthioamides in synthesis(II): an efficient one-pot, threecomponent synthesis of tricyclic thiochromeno[2,3-*b*]pyridine derivatives. *Tetrahedron* 2009, 65, 1287–1293.

(36) Wen, L.-R.; Sun, J.-H.; Li, M.; Sun, E.-T.; Zhang, S.-S. Application of b-(2-Chloroaroyl) Thioacetanilides in Synthesis: An Unusual and Highly Efficient Access to Thiochromeno[2,3-b]pyridine Derivatives. J. Org. Chem. 2008, 73, 1852–1863.

(37) Wen, L.-R.; Shi, Y.-J.; Liu, G.-Y.; Li, M. Modulating the reactivity of functionalized N,S-ketene acetal in MCR: selective synthesis of tetrahydropyridines and thiochromeno[2,3-b]pyridines via DABCO-catalyzed tandem annulation. *J. Org. Chem.* **2012**, *77*, 4252–4260.

(38) Abbas, E. M. H.; Gomha, S. M.; Farghaly, T. A. Multicomponent reactions for synthesis of bioactive polyheterocyclic ring systems under controlled microwave irradiation. *Arabian J. Chem.* **2014**, *7*, 623–629.

(39) Ibrahim, H. M.; Behbehani, H. Palladium-catalyzed Q-tubeassisted protocol for synthesizing diaza-dibenzo[a,e]azulene and diazabenzo[a]fluorene derivatives via O2 acid-promoted cross-dehydrogenative coupling. J. Org. Chem. 2020, 85, 15368–15381.

(40) Behbehani, H.; Aryan, F. A.; Dawood, K. M.; Ibrahim, H. M. High pressure assisted synthetic approach for novel 6,7-dihydro-SHbenzo[6,7]cyclohepta[1,2-b]pyridine and 5,6-dihydrobenzo[h] quinoline derivatives and their assessment as anticancer agents. *Sci. Rep.* **2020**, *10*, 21691.

(41) Ibrahim, H. M.; Ahmed Arafa, W. A.; Behbehani, H. L-Proline catalyzed one-pot synthesis of polysubstituted pyridine system incorporating benzothiazole moiety via sustainable sonochemical approach. *RSC Adv.* **2018**, *8*, 37606–37617.

(42) Behbehani, H.; Ibrahim, H. M. Microwave assisted synthesis in water. First one pot synthesis of a novel class of polysubstituted benzo[4,5]imidazo[1,2-b]pyridazines via intramolecular SNAr. *RSC Adv.* **2015**, *5*, 89226–89237.

(43) Ibrahim, H. M.; Behbehani, H.; Mostafa, N. S. Scalable sonochemical synthetic strategy for pyrazolo[1,5-*a*]pyridine derivatives: First catalyst free concerted [3+2] cycloaddition of alkyne and alkene derivatives to 2-imino-1H-pyridin-1-amines. *ACS Omega* **2019**, *4*, 7182–7193.

(44) Ibrahim, H. M.; Behbehani, H.; Ahmed Arafa, W. A. A facile, practical and metal-free microwave-assisted protocol for mono- and bis- [1,2,4]triazolo[1,5-*a*]pyridines synthesis utilizing 1-amino-2-iminopyridine derivatives as a versatile precursor. *RSC Adv.* 2020, 10, 15554–15572.

(45) Ibrahim, H. M.; Behbehani, H. The first Q-Tube based high pressure synthesis of anti-cancer active thiazolo[4,5-*c*]pyridazines via the [4+2] cyclocondensation of 3-oxo-2-arylhydrazonopropanals with 4-thiazolidinones. *Sci. Rep.* **2020**, *10*, 6492.

(46) Behbehani, H.; Ibrahim, H. M. Synthetic strategy for pyrazolo[1,5-a]pyridine and pyrido[1,2-b]indazole derivatives through AcOH and O₂-promoted cross-dehydrogenative coupling reactions between 1,3-dicarbonyl compounds and N-amino-2-iminopyridines. ACS Omega **2019**, 4, 15289–15303.

(47) (a) Ibrahim, H. M.; Behbehani, H. Sustainable Synthetic Approach for (Pyrazol-4-ylidene)pyridines By Metal Catalyst-Free Aerobic $C(sp^2)-C(sp^3)$ Coupling Reactions between 1-Amino-2-imino-pyridines and 1-Aryl-5-pyrazolones. ACS Omega **2019**, 4, 11701–11711. (b) Behbehani, H.; Ibrahim, H. M.; Dawood, K. M. Ultrasound-assisted regio- and stereoselective synthesis of bis-[1',4'-diaryl-1-oxo-spiro-benzosuberane-2,5'-pyrazoline] derivatives via 1,3-dipolar cycloaddition. RSC Adv. **2015**, 5, 25642–25649.

(48) Mo, F.; Dong, G. Regioselective ketone α -alkylation with simple olefins *via* dual activation. *Science* **2014**, *345*, 68–72.

(49) Sancineto, L.; Monti, B.; Merlino, O.; Rosati, O.; Santi, C. Q-Tube assisted MCRs for the synthesis of 2,3-dihydroquinazolin-4(1H)-ones. *Arkivoc* **2018**, 2018, 270–278.

(50) Nacca, F. G.; Merlino, O.; Mangiavacchi, F.; Krasowska, D.; Santi, C.; Sancineto, L. The Q-tube system, a nonconventional technology for green chemistry practitioners. *Curr. Green Chem.* **2017**, *4*, 58–66.

(51) Oliverio, M.; Costanzo, P.; Nardi, M.; Rivalta, I.; Procopio, A. Facile ecofriendly synthesis of monastrol and its structural isomers *via* biginelli reaction. *ACS Sustain. Chem. Eng.* **2014**, *2*, 1228–1233.

(52) Costanzo, P.; Calandruccio, C.; Di Gioia, M. L.; Nardi, M.; Oliverio, M.; Procopio, A. First multicomponent reaction exploiting glycerol carbonate synthesis. *J. Clean. Prod.* **2018**, *202*, 504–509.

(53) Taddei, M.; Mura, M. G.; Rajamäki, S.; Luca, L. D.; Porcheddu, A. Palladium-catalysed dehydrogenative generation of imines from amines. A nature-inspired route to indoles *via* cross-couplings of amines with arylhydrazines. *Adv. Synth. Catal.* **2013**, 355, 3002–3013.

(54) Palomba, M.; Rossi, L.; Sancineto, L.; Tramontano, E.; Corona, A.; Bagnoli, L.; Santi, C.; Pannecouque, C.; Tabarrini, O.; Marini, F. A new vinyl selenone-based domino approach to spirocyclopropyl oxindoles endowed with anti-HIV RT activity. *Org. Biomol. Chem.* **2016**, *14*, 2015–2024.

(55) Lee, J.; Ryu, T.; Park, S.; Lee, P. H. Indium tri(isopropoxide)catalyzed selective meerwein-ponndorf-verley reduction of aliphatic and aromatic aldehydes. *J. Org. Chem.* **2012**, *77*, 4821–4825. (56) The crystallographic data for **4s** (ref. CCDC 2110964), can be obtained on request from the director, Cambridge Crystallographic Data Center, 12 Union Road, Cambridge CB2 1EW, UK.

34074